Parkinson’s disease primarily destroys a tiny cluster of cells deep in the midbrain called the substantia nigra pars compacta, where roughly 400,000 to 500,000 dopamine-producing neurons sit on each side of the brain. But the damage doesn’t stop there. The disease follows a predictable path through the brain over years and decades, eventually reaching areas responsible for mood, sleep, memory, and thinking.
The Substantia Nigra: Where It Starts to Matter
The substantia nigra pars compacta is a small structure that punches far above its weight. Despite making up a minuscule portion of total brain mass, these dopamine-producing neurons have an outsized influence on movement and behavior. When enough of them die, the hallmark motor symptoms of Parkinson’s appear: tremor, stiffness, slowness, and balance problems.
For a long time, textbooks stated that motor symptoms appeared after about 50 to 70 percent of these neurons were lost. More recent quantitative studies have revised that number downward. Motor signs likely emerge when around 30 percent of substantia nigra neurons have died compared to age-matched healthy brains. That still means a significant amount of damage has already occurred before anyone notices a tremor.
These neurons are especially vulnerable for a biological reason. They have extremely large, highly branched structures with an enormous number of connection points, and they fire constantly to maintain a tonic rhythm. All of this demands unusually high energy. The amount of fuel (ATP) a neuron needs to restore its electrical charge after firing increases exponentially with the size and complexity of its branching. Substantia nigra neurons are essentially running at full throttle all the time, which makes them uniquely sensitive to anything that disrupts their energy supply or exposes them to oxidative stress.
The Basal Ganglia Circuit
The substantia nigra doesn’t work alone. It’s part of a larger network called the basal ganglia, a group of interconnected structures that fine-tune movement. Within this circuit, two pathways originate from the striatum, a key relay station. The “direct pathway” promotes movement, while the “indirect pathway” inhibits it. Dopamine from the substantia nigra helps balance these two systems so you can move smoothly and intentionally.
When dopamine levels drop, that balance collapses. The subthalamic nucleus, a small lens-shaped structure, becomes overactive. This drives excessive output from a region called the globus pallidus internus, which acts like a brake on movement. The result is too much inhibition: muscles stiffen, movements slow down, and initiating a step or reaching for a cup becomes effortful. This is why deep brain stimulation surgery targets either the subthalamic nucleus or the globus pallidus internus. Electrical impulses delivered to these areas help restore the chemical balance within the basal ganglia and reduce motor symptoms.
How the Disease Spreads Through the Brain
Parkinson’s doesn’t begin in the substantia nigra. The pathological process actually starts earlier and lower, in the brainstem and the olfactory system. In a now-landmark staging system proposed by Heiko Braak in 2003, the earliest damage appears in the nerve center that controls the vagus nerve (which connects the brain to the gut) and in the area that processes smell. This is why loss of smell and digestive problems often appear years before any tremor.
From these initial sites, the disease follows an ascending course through the brainstem with remarkably little variation between individuals. It climbs upward, eventually reaching the substantia nigra (when motor symptoms begin), then continues into higher brain structures. The agent driving this spread is a misfolded protein called alpha-synuclein, which clumps together inside neurons to form deposits known as Lewy bodies. Research in animal models has shown that this protein can transmit its abnormal shape from neuron to neuron along established brain pathways, like a chain reaction. The misfolded protein from outside a cell disappears within about a week, but it has already corrupted the cell’s own proteins, which begin forming new clumps roughly three months later.
In a long-term study of patients with Parkinson’s, it took an average of 13 years for these protein deposits to reach the brain’s limbic regions (involved in emotion and memory) and 18 years before they appeared in the association cortices (involved in higher thinking) in half of cases.
The Locus Coeruleus and Non-Motor Symptoms
One of the brain regions hit along the way is the locus coeruleus, a small brainstem structure that produces norepinephrine, a chemical messenger involved in alertness, mood, and the body’s stress response. Degeneration here has been recognized as a distinct early subtype of the disease, sometimes called noradrenergic Parkinson’s.
Loss of norepinephrine-producing neurons and their widespread connections throughout the brain and body drives a range of non-motor symptoms that can be just as disabling as tremor. These include REM sleep behavior disorder (where people physically act out dreams), chronic pain, anxiety, depression, and early cognitive difficulties. As these neurons degrade, the brain attempts to compensate by releasing more norepinephrine from surviving fibers and increasing the sensitivity of the receptors that detect it. This compensatory response may itself contribute to anxiety, which is one of the most common early symptoms of Parkinson’s, often appearing before any motor signs.
Cortical Thinning and Cognitive Decline
In later stages, the disease reaches the cerebral cortex, the outer layer of the brain responsible for thinking, perception, and decision-making. This doesn’t happen all at once. It follows a specific sequence: the inner surface of the temporal lobe is affected first, followed by higher-order sensory and prefrontal areas, and finally the primary sensory and motor regions.
When dementia develops in Parkinson’s, brain imaging reveals measurable thinning across wide areas of the cortex. People with Parkinson’s-related dementia show significantly thinner tissue in the sensorimotor regions (which coordinate movement and sensation), the lateral parietal cortex (spatial awareness and attention), temporal and occipital regions (visual processing and memory), and frontal areas (planning and judgment). The degree of cortical thinning in sensorimotor and posterior cingulate areas correlates directly with performance on cognitive screening tests. In other words, the thinner these regions become, the lower the cognitive scores.
Not everyone with Parkinson’s develops dementia. Those who maintain relatively stable cognition tend to have pathology that stays at moderate Braak stages (IV or less), while those who develop dementia typically show advanced cortical involvement (stages V through VI). The progression from motor disease to cognitive disease is not inevitable, but the risk increases significantly with disease duration.
Putting the Pieces Together
Parkinson’s is often thought of as a movement disorder, and the substantia nigra’s dopamine loss is the centerpiece of that story. But the disease is really a whole-brain process that unfolds over decades. It begins in the brainstem and olfactory system, climbs through the midbrain where it destroys the dopamine neurons responsible for motor control, disrupts norepinephrine systems that regulate sleep and mood, and eventually reaches the cortex where it can impair thinking and memory. Each affected region produces its own set of symptoms, which is why Parkinson’s looks so different from person to person and changes so much over time.